公开(公告)号：EP1268530B1

公开(公告)日：2006-08-16

申请号：EP01919645.0

申请日：2001-04-09

申请人： UNIVERSITY OF LEEDS

发明人： GEHIN, A. School of Biochem. and Molecular Biology ,  GILBERT, R. Univ. of Oxford Div. of Struc. Biology ,  STUART, D. Univ. of Oxford Div. of Struc. Biology ,  ROWLANDS, D. School of Biochem. and Molecular Bio.

IPC分类号： C07K14/02 ,  C12N15/62 ,  A61K39/29 ,  A61K39/295

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/53 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/735 ,  C07K2319/80 ,  C12N15/62 ,  C12N2730/10122 ,  Y02A50/466

摘要： The hepatitis B virus (HBV) capsid is made up of a single species of protein called the core antigen (HBcAg) which self-assembles into particles. The particles are highly immunogenic and are able to present heterologous epitopes to the immune system when the epitopes are inserted into a surface-exposed region of the particles called the "e1 loop". The structural building blocks of the particles are tightly associated dimers of HBcAg in which the adjacent e1 loops are closely juxtaposed. It is proposed that sequences inserted into the e1 loop are conformationally restrained in the assembled particles when presented in monomeric core protein. The invention seeks to solve this problem by covalently linking core proteins as tandem copies (e.g., as dimers) so that insertions can be made independently in each copy. This is particularly useful for insertion of large sequences into the e1 loop because it allows such sequences to be inserted into just one copy of the core protein per tandem repeat, thereby reducing potential conformational clashes in assembly. Alternatively, a different sequence may be inserted into each e1 loop of a tandem repeat, thus increasing the flexibility of HBcAg particles as an epitope delivery system.

公开(公告)号：EP1535927A4

公开(公告)日：2006-06-21

申请号：EP03794268

申请日：2003-09-05

申请人： ADVANCED LIFE SCIENCE INST INC

发明人： MAKI NOBORU ,  KIMURA TATSUJI ,  YAGI SHINTARO

IPC分类号： A61P1/16 ,  A61P31/12 ,  C07K14/02 ,  C07K14/08 ,  C12N7/04 ,  G01N33/576 ,  A61K39/29 ,  C12N7/00

CPC分类号： C07K14/005 ,  A61K2039/5258 ,  C12N7/00 ,  C12N2730/10122 ,  C12N2730/10123 ,  G01N33/5761

摘要： It is intended to provide an HBV precore protein capable of forming particles and a means of assaying the same. A novel HBV precore protein forming HBV virus-like particles is identified. Thus, this novel HBV precore protein is provided. It is also intended to provide core-like particles and virus-like particles formed by this HBV precore protein. These virus-like particles are usable in vaccines and remedies. Moreover, it is intended to provide a method of assaying the HBV precore protein and a method of assaying an anti-HBV precore protein antibody.

公开(公告)号：EP1587816A4

公开(公告)日：2006-06-07

申请号：EP03814236

申请日：2003-12-19

申请人： VICAL INC

发明人： HERMANSON GARY G ,  GEALL ANDREW J ,  WLOCH MARY KOPKE

IPC分类号： C07H21/00 ,  C07H21/04 ,  C07K14/02 ,  C07K14/045 ,  C12Q1/70

CPC分类号： A61K38/16 ,  A61K35/763 ,  A61K38/162 ,  A61K39/00 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/53 ,  A61K2039/55522 ,  A61K2039/55555 ,  A61K2039/55572 ,  C07H21/00 ,  C07K14/005 ,  C07K14/045 ,  C12N2710/16122 ,  C12N2710/16134 ,  C12N2800/22

摘要： The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IEI, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators.

公开(公告)号：EP1558628A4

公开(公告)日：2006-05-31

申请号：EP03751670

申请日：2003-09-25

申请人： STATE RES CT OF VIROLOGY AND B

发明人： MAKSYUTOV AMIR ZAKIEVICH ,  RYZHIKOV ALEXANDER BORISOVICH ,  KOLOBOV ALEXANDER ALEXANDROVIC ,  MAKSYUTOV ZAKI AMIROVICH

IPC分类号： C07K14/155 ,  A61K38/00 ,  A61K39/00 ,  A61K39/21 ,  A61P31/12 ,  A61P31/18 ,  C07K1/04 ,  C07K14/02 ,  C07K14/11 ,  C07K14/16 ,  C07K14/18 ,  C07K14/35 ,  C07K14/445 ,  C07K1/00 ,  A61K39/02 ,  A61K39/12 ,  C07K14/005 ,  C07K14/195

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55566 ,  C07K1/047 ,  C07K14/35 ,  C07K14/445 ,  C12N2730/10122 ,  C12N2740/16111 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16222 ,  C12N2760/16122 ,  C12N2770/24222

摘要： A method for designing antigenic peptide libraries accounts for naturally occurring and potential variability in a group of protein sequences from a variable pathogen. The peptide libraries can elicit an immune response against a range of pathogen variants.

公开(公告)号：EP1658367A2

公开(公告)日：2006-05-24

申请号：EP04767871.9

申请日：2004-07-05

申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

发明人： CHEMIN, Isabelle ,  TREPO, Christian

IPC分类号： C12N15/00 ,  C07K14/02 ,  A61K48/00 ,  C12Q1/68 ,  C07K16/08 ,  C12N15/34 ,  A61K39/12

CPC分类号： C07K14/005 ,  A61K48/00 ,  A61K2039/525 ,  C12N2730/10122

摘要： The invention relates to an isolated nucleic acid sequence, obtainable from the genome of the HXHV virus, in particular, the nucleic acid sequence comprising the sequence SEQ ID NO: 4 or the complementary sequence to SEQ ID NO: 4, polypeptides coded by said nucleic acid sequences and uses thereof.

公开(公告)号：EP1218514B1

公开(公告)日：2006-04-26

申请号：EP00964541.7

申请日：2000-10-06

申请人： Celltech Pharma Europe Limited

发明人： JONES, C. Elan Corp. ,  BACON, A. Lipoxen Technologies Limited ,  DOUCE, G. Divisin of Infection & Immunity, IBLS ,  PAGE, M. Apovia AG

IPC分类号： C12N15/36 ,  C07K14/02 ,  A61K39/12 ,  A61P37/02 ,  C12N15/62

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K2039/55555 ,  A61K2039/57 ,  C07K2319/00 ,  C12N2730/10122 ,  C12N2740/16122

摘要： The invention provides a method for designing protein immunogen, which comprises (a) modifying the amino acid sequence of the immunogen, and (b) determining whether the T-helper (Th) cell response to the modified immunogen is of the Th1 type or the Th2 type. The method is useful in identifying immunogens for use in immunotherapy of diseases. For example, chronic hepatitis is believed to be associated with a Th2-dominated response which fails to clear the virus, and switching the Th response to a Th1 response by administration of an immunogen that induces a Th1 response may help in clearing the virus.

公开(公告)号：EP1294893B1

公开(公告)日：2006-03-15

申请号：EP01943625.2

申请日：2001-06-22

申请人： UCB Pharma Limited

发明人： PAGE, Mark ,  LI, Jing-Li ,  PUMPENS, Paul Biomedical Research and Study Centre ,  BORISOVA, Galina, Biomedical Research& Study Ctr.

IPC分类号： C12N15/51 ,  C07K14/02 ,  A61K39/29 ,  A61P31/20

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K48/00 ,  A61K2039/525 ,  C12N2730/10122 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/412 ,  Y02A50/466 ,  Y02A50/484

摘要： A protein is provided comprising hepatitis B core antigen (HBcAg) wherein one or more of the four arginine repeats has been deleted, said protein comprising the C-terminal cysteine of HBcAg. The deleted region may be replaced by an epitope from a protein other than HBcAg, in which case the HBcAg acts as a carrier to present the epitope to the immune system. The chimeric protein is useful in prophylactic and therapeutic vaccination of a host, for example against hepatitis B virus.

公开(公告)号：EP1333857A4

公开(公告)日：2006-02-22

申请号：EP01964615

申请日：2001-08-16

申请人： APOVIA INC

发明人： BIRKETT ASHLEY J

IPC分类号： C12N15/09 ,  A61K39/00 ,  A61K39/39 ,  C07K14/02 ,  C07K14/09 ,  C07K14/15 ,  C07K14/16 ,  C07K14/445 ,  C07K14/47 ,  C07K14/50 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N5/10 ,  C12N9/02 ,  C12N15/36 ,  C12R1/84 ,  A61K39/29 ,  A61K39/02 ,  A61K39/385 ,  C07H21/04

CPC分类号： C07K14/005 ,  A61K2039/5258 ,  A61K2039/54 ,  A61K2039/555 ,  A61K2039/57 ,  C07K14/445 ,  C07K14/4711 ,  C07K14/50 ,  C07K2319/00 ,  C12N9/0077 ,  C12N2730/10122 ,  C12N2740/13022 ,  C12N2740/16222 ,  C12N2770/32122

摘要： A chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid protein (HBc) is disclosed that is engineered for both enhanced stability of self-assembled particles and the display of an immunogenic epitope. The display of the immunogenic epitope is displayed in the immunogenic loop of HBc, whereas the enhanced stability of self-assembled particles is obtained by the presence of at least one heterologous cysteine residue near the carboxy-terminus of the chimer molecule. Methods of making and using the chimers are also disclosed.

公开(公告)号：EP1619207A3

公开(公告)日：2006-02-08

申请号：EP05016493.8

申请日：2000-09-01

申请人： Epimmune Inc.

发明人： Grey, Howard M. ,  Sette, Alessandro ,  Sidney, John ,  Southwood, Scott

IPC分类号： C07K16/00 ,  C07H21/04 ,  A61K39/00 ,  C07K14/02 ,  C07K14/03 ,  C07K14/08 ,  C07K14/11 ,  C07K14/16 ,  C07K14/18 ,  C12N9/90 ,  C07K7/06 ,  A61K39/29

CPC分类号： C07K14/005 ,  A61K39/0011 ,  A61K2039/57 ,  C12N9/90 ,  C12N2730/10122 ,  C12N2740/16222 ,  C12N2760/16122 ,  C12N2770/24222

摘要： An isolated HCV peptide of 15 residues or less, comprising a sequence selected from the group consisting of:

KLVALGINAV (SEQ ID NO:175)
SLMAFTAAV (SEQ ID NO:176)
CINGVCWTV (SEQ ID NO:177)
TISGVLWQV (SEQ ID NO:178)
SISGVLWQV (SEQ ID NO:179)
SLMAFTASV(SEQ ID NO:180)
GLRDCTMLV (SEQ ID NO:181)
KLVALGVNAV(SEQ ID NO:182)
KLSGLGLNAV (SEQ ID NO:183)
LLCPAGHAV (SEQ ID NO:186)
LLFNILGWV (SEQ ID NO:187) and

any of the above sequences modified by one or two conservative substitutions.

公开(公告)号：EP1135476A4

公开(公告)日：2006-01-25

申请号：EP99957236

申请日：1999-11-10

申请人： MELBOURNE HEALTH

发明人： LOCARNINI STEPHEN ALISTER ,  TORRESI JOSEPH ,  EARNEST-SILVEIRA LINDA ,  BARTHOLOMEUSZ ANGELINE INGRID

IPC分类号： A61K39/00 ,  C07K14/02 ,  C12N7/04 ,  C12N15/00 ,  A61K39/29

CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N7/00 ,  C12N2730/10122 ,  C12N2730/10161